GLP-1 Patches: Are They an Option?

What Are GLP-1 Receptor Agonists?

GLP-1 stands for glucagon-like peptide-1, a natural hormone that helps regulate blood sugar, appetite, and digestion. GLP-1 receptor agonists are medications that mimic the action of this hormone, activating receptors in the pancreas, brain, and gut to support metabolic function.

Certain GLP-1 medications are FDA-approved to manage Type 2 diabetes (e.g., Ozempic®, Trulicity®) and chronic weight management (e.g., Wegovy®, Saxenda®) in adults with obesity or overweight and related health conditions.

Currently, GLP-1s are administered via subcutaneous injections (daily or weekly) or oral tablets, such as Rybelsus®, which contains semaglutide in pill form.

‍

Are GLP-1 Patches Available Today?

As of now, no GLP-1 patch has received FDA approval for clinical use in the United States.

Most GLP-1 medications on the market, such as semaglutide, liraglutide, or dulaglutide, are peptide-based drugs. Peptides are large molecules that are typically broken down in the digestive system and do not easily pass through the skin; therefore, these medications require injection or specialized oral formulations with absorption enhancers.

That said, researchers and pharmaceutical companies are exploring transdermal delivery technologies, including microneedle patches, to potentially deliver GLP-1 receptor agonists in the future.

‍

{{primary-cta}}

‍

What Does the Research Say About GLP-1 Patches?

Though still in early stages, a few preclinical studies have examined how GLP-1 medications might be delivered through the skin using novel delivery systems.

For example, a 2024 preclinical study published in Advanced Drug Delivery & Translational Research explored a microneedle patch designed to deliver GLP-1 analogs transdermally in mice. The patch used biodegradable microneedles to gradually release the drug and showed promising metabolic effects in animal models. However, this technology remains investigational, is not approved for human use, and has not progressed to clinical trials. 

Some research has also explored transdermal gels or films. Still, similar limitations exist, particularly with large, fragile molecules like GLP-1 analogs, which are difficult to deliver consistently and safely through the skin barrier without advanced enhancement technologies.

Bottom line: There is no FDA-approved GLP-1 patch currently on the market, and the science is still evolving.

‍

Why Are GLP-1 Patches So Challenging to Develop?

Delivering medication through the skin isn't as simple as it sounds, especially for complex molecules like GLP-1 receptor agonists. Here’s why:

• Peptides are large and cannot easily pass through the outer layers of the skin.
  
• Enzymes in the skin can break down the drug before it reaches circulation.
  
• Dose control can be difficult with patch-based delivery for these types of medications.
  
• The bioavailability (amount of drug absorbed) is generally lower with transdermal methods than with injections or specialized oral forms.
  
  

While microneedle and nanocarrier technologies are being tested, it may be years before any patch-based GLP-1 medication is proven effective and approved for use in humans.

‍

What Options Are Available Today?

Currently, the only GLP-1 medications approved for clinical use are injectable and oral:

‍

‍

Each formulation comes with specific instructions, absorption considerations, and dosing schedules. A licensed healthcare provider can help determine which option is best for you, based on your medical history, lifestyle, and goals, when appropriate.

‍

{{primary-cta}}

‍

What Should You Ask a Provider?

If you're interested in GLP-1 medications but have concerns about injections or daily pills, a licensed provider can walk you through:

• All available GLP-1 options that the FDA currently approves
  
• What to expect from each form (oral vs. injectable)
  
• How dosing, scheduling, and side effects may vary
  
• Whether you're a candidate for treatment based on a full health assessment
  
  

At Eden, we make it simple to connect with independent, licensed providers who take the time to understand your needs and build a personalized plan, without pushing unproven or unavailable treatments. Eden does not manufacture or make any medications.

‍

Conclusion

GLP-1 patches are not currently an option, but they’re an exciting area of research. Currently, injectable and oral GLP-1 receptor agonists are the only forms approved for clinical use in metabolic health management.

If you’re exploring treatment options, your best next step is to speak with a licensed healthcare provider who can walk you through what’s available today, what’s in development, and what makes the most sense for your body and goals.

‍

‍